Research programme: oral therapeutics - Global Blood Therapeutics

Drug Profile

Research programme: oral therapeutics - Global Blood Therapeutics

Alternative Names: GB 18713; GBT 018713; GBT 1118

Latest Information Update: 04 Aug 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Global Blood Therapeutics
  • Class Small molecules
  • Mechanism of Action Haemoglobin modulators; Kallikrein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Hereditary angioedema; Hypoxia

Most Recent Events

  • 13 May 2016 Pharmacodynamics data from a preclinical study presented at the 112th International Conference of the American Thoracic Society
  • 29 Mar 2016 Global Blood Therapeutics intends to file an IND application with the US FDA in USA for Hereditary angioedema (Global Blood Therapeutics 10-K, March 2016)
  • 29 Mar 2016 Global Blood Therapeutics plans a phase I trial for Hereditary angioedema in USA (Global Blood Therapeutics 10-K, March 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top